Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Esperion Tl Form 4	herapeutics, Inc.											
June 10, 20	16											
FORM	Л 4		~~~~			~~~		~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		PPROVAL		
Washington, D.C. 20549									N OMB Number:	3235-0287		
Check this box if no longer CT A TENTENTE OF CHANGES IN DENEFLOIAL ON DEPOSITION								WNEDCHIDAI	Expires:	January 31, 2005		
subject to Section 16. Form 4 or						ICIA	AL UV	Estimated burden hou	Estimated average ourden hours per esponse 0.5			
Form 5	Filed put	rsuant to S	Section	16(a) of th	ne Securi	ties I	Excha	nge Act of 1934,	•	. 0.0		
obligati may con <i>See</i> Inst 1(b).	ntinue. Section 17(Jtility Hol nvestment	•	-	•	of 1935 or Secti 940	on			
(Print or Type	Responses)											
1. Name and MCGOVE	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer					
(Lest)	(First)	Middle)	Esperion Therapeutics, Inc. [ESPR					(Check all applicable)				
(Last)	(First) (wildule)		of Earliest T 'Day/Year)	ransaction			X_ Director 10% Owner				
C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE, SUITE 150			06/09/2016					Officer (give title Other (specify below)				
				4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 					
ANN ARB	OR, MI 48108							Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tal	ble I - Non-l	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deem Execution any (Month/D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						(A)		Reported Transaction(s)				
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
				Code v	Amount	(D)	Flice					
Reminder: Re	eport on a separate line	e for each cl	ass of sec	curities bene	Perso	ons w	ho res	spond to the colle		SEC 1474		
					requi	red to ays a	o respo	ained in this forn ond unless the fo ntly valid OMB cc	rm	(9-02)		
	Tab			curities Acq ls, warrants		-		Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction of Derivativ	e Expiration Date	Underlying Securities	Der

Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year) (Instr.		Code (Instr. 8	3) . I	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		Sec (In:
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 17.75	06/09/2016		А		8,000		<u>(1)</u>	06/09/2026	Common Stock	8,000	

Reporting Owners

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
MCGOVERN MARK E C/O ESPERION THERAPEUTICS INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108	Х			
Signatures				
/s/ Richard B. Bartram, by power of attorney	0	6/10/2016		
**Signature of Reporting Person		Date		
Explanation of Respons	es:			

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vest in full on the earlier of (i) June 9, 2017 and (ii) the Issuer's next annual meeting of stockholders following June 9, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.